
SGMO
Sangamo Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.560
Open
0.520
VWAP
0.53
Vol
6.13M
Mkt Cap
162.80M
Low
0.5111
Amount
3.27M
EV/EBITDA(TTM)
--
Total Shares
207.51M
EV
117.79M
EV/OCF(TTM)
--
P/S(TTM)
1.43
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
26.40M
-46.57%
--
--
13.18M
+74.55%
--
--
20.55M
+219.25%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Sangamo Therapeutics, Inc. (SGMO) for FY2025, with the revenue forecasts being adjusted by -6.12% over the past three months. During the same period, the stock price has changed by 17.30%.
Revenue Estimates for FY2025
Revise Downward

-6.12%
In Past 3 Month
Stock Price
Go Up

+17.30%
In Past 3 Month
6 Analyst Rating

659.82% Upside
Wall Street analysts forecast SGMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMO is 4.10 USD with a low forecast of 1.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy

659.82% Upside
Current: 0.540

Low
1.50
Averages
4.10
High
10.00

659.82% Upside
Current: 0.540

Low
1.50
Averages
4.10
High
10.00
Barclays
Overweight
downgrade
$9 -> $5
2025-05-14
Reason
Barclays
Price Target
$9 -> $5
2025-05-14
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Sangamo to $5 from $9 and keeps an Overweight rating on the shares. The company's Q1 call provided additional color on cash runway extended into late Q3 by the capital raise, the analyst tells investors in a research note.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$10
2025-04-07
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$10
2025-04-07
Reiterates
Strong Buy
Reason
RBC Capital
Luca Issi
Hold
Reiterates
$2
2025-03-18
Reason
RBC Capital
Luca Issi
Price Target
$2
2025-03-18
Reiterates
Hold
Reason
Truist Securities
Nicole Germino
Strong Buy
Maintains
$7 → $5
2025-01-23
Reason
Truist Securities
Nicole Germino
Price Target
$7 → $5
2025-01-23
Maintains
Strong Buy
Reason
Truist analyst Nicole Germino lowered the firm's price target on Sangamo to $5 from $7 and keeps a Buy rating on the shares. The firm is updating its model to reflect the return of a BLA-ready Phase 3 asset with competitive data in Hem A and pending more clarity on the longer-term cash position from a potentially near-term announcement of a partner for Phase 3 Fabry disease asset and additional capsid partnerships, the analyst tells investors in a research note. Truist adds that the longer-term cash runway for Sangamo hinges on a partner for Fabry, which may come with a meaningful upfront and royalties payments, removing the cash overhang.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$10
2025-01-02
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$10
2025-01-02
Reiterates
Strong Buy
Reason
Wells Fargo
Jim Birchenough
Hold
Maintains
$3 → $2
2024-12-31
Reason
Wells Fargo
Jim Birchenough
Price Target
$3 → $2
2024-12-31
Maintains
Hold
Reason
Wells Fargo analyst Yanan Zhu lowered the firm's price target on Sangamo to $2 from $3 and keeps an Equal Weight rating on the shares. The firm says Pfizer's return of Sangamo's hemophilia A program, so close to the planned biologics license application filing, came as a surprise. The key implication is that Sangamo is no longer eligible for $220M in regulatory and first-sales milestones, the analyst tells investors in a research note. Wells believes this further increases funding pressure on Sangamo. The company's cash position can fund operations into Q1 of 2025, and the company is seeking to partner its Fabry gene therapy program in an effort to extend cash runway, adds Wells.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Sangamo Therapeutics Inc (SGMO.O) is -1.96, compared to its 5-year average forward P/E of -4.79. For a more detailed relative valuation and DCF analysis to assess Sangamo Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-4.79
Current PE
-1.96
Overvalued PE
-0.13
Undervalued PE
-9.45
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.87
Current EV/EBITDA
-2.32
Overvalued EV/EBITDA
27.11
Undervalued EV/EBITDA
-25.37
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
7.37
Current PS
1.63
Overvalued PS
12.76
Undervalued PS
1.98
Financials
Annual
Quarterly
FY2025Q2
YoY :
+5042.13%
18.31M
Total Revenue
FY2025Q2
YoY :
-47.53%
-17.86M
Operating Profit
FY2025Q2
YoY :
-44.68%
-19.99M
Net Income after Tax
FY2025Q2
YoY :
-55.56%
-0.08
EPS - Diluted
FY2025Q2
YoY :
-32.37%
-18.18M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
YoY :
-96.96%
-44.29
FCF Margin - %
FY2025Q2
YoY :
-98.92%
-109.18
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SGMO News & Events
Events Timeline
2025-06-24 (ET)
2025-06-24
08:17:26
Sangamo announces topline results from STAAR study

2025-05-12 (ET)
2025-05-12
18:28:21
Sangamo backs FY25 operating expenses view $135M-$155M

2025-05-12
18:27:39
Sangamo reports Q1 EPS (14c) vs (27c) last year

Sign Up For More Events
Sign Up For More Events
News
9.5
08-08NewsfilterSangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript
9.0
06-24NewsfilterSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
9.0
06-24NASDAQ.COMSangamo Therapeutics Reports Positive Data From Phase 1/2 STAAR Study In Fabry Disease
Sign Up For More News
People Also Watch

TVGN
Tevogen Bio Holdings Inc
1.010
USD
+4.88%

BPRN
Princeton Bancorp Inc
33.300
USD
+0.82%

ELLO
Ellomay Capital Ltd
17.600
USD
-2.22%

RCEL
AVITA Medical Inc
5.760
USD
+4.35%

CHMG
Chemung Financial Corp
52.480
USD
+1.00%

ARAY
Accuray Inc
1.490
USD
+0.68%

SVRE
Saverone 2014 Ltd
2.060
USD
+1.23%

ABEO
Abeona Therapeutics Inc
6.560
USD
+2.82%

VUZI
Vuzix Corp
2.320
USD
+5.45%

KFS
Kingsway Financial Services Inc
14.230
USD
+2.97%
FAQ

What is Sangamo Therapeutics Inc (SGMO) stock price today?
The current price of SGMO is 0.5396 USD — it has increased 4.25 % in the last trading day.

What is Sangamo Therapeutics Inc (SGMO)'s business?

What is the price predicton of SGMO Stock?

What is Sangamo Therapeutics Inc (SGMO)'s revenue for the last quarter?

What is Sangamo Therapeutics Inc (SGMO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Sangamo Therapeutics Inc (SGMO)'s fundamentals?

How many employees does Sangamo Therapeutics Inc (SGMO). have?
